
Welcome to Provider Office Hours

During the session, please use the Q&A panel to comment or ask a question:

Q&A Panel







Housekeeping

Reminder to Panelists:

Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Participants:

Please access today's slides and archived presentations at: <u>https://eziz.org/covid/</u>



Agenda

Guest Speaker

- Allocation Update Larry Hilty, Vice President, Enterprise Transformation & Operations
- Trust & Safety Team Angela Eaddy

Announcements

- Weekly VA58 Newsletter Amy Pine
- Janssen COVID-19 Vaccine Educational Webinars Amy Pine
- My Turn in 12 Languages Amy Pine
- Vaccinate All 58 communications report Asbury Jones

Vaccine Updates

- Allocations Amy Pine
- myCAvax Claudia Aguiluz
- Storage & Handling Kate McHugh
- Provider Call Center Brenton Louie









Allocation Update

Larry Hilty Vice President, Enterprise Transformation & Operations





Accelerating Vaccine Distribution and Administration for Californians

March 26, 2021



Information contained in this file is confidential, preliminary, and pre-decisional



What we are trying to deliver as we build and expand the network

California's Statewide Vaccine Network is designed to save more lives.

Delivering an improved and connected experience



Vaccinate ALL 58

More options to vaccinate Californians faster	 Statewide network of providers Geographically diverse mega sites Home visits Mobile providers Pharmacies
More resources to reach diverse communities	 Network designed to reach the most vulnerable and those disproportionately affected by COVID-19 infection and death Support to providers and local health jurisdictions for FEMA-eligible costs associated with supporting the transition to a new system and workflow Patient navigators Support services, including extended hours, language capacity, accommodations for physical accessibility and mobile clinics
More user data and reporting for transparency	 A more consistent and reliable user experience for all Californians Timely data sharing Daily allocation reports to ensure equity, efficiency, and speed of network Ongoing community and stakeholder engagement

Source: CA COVID-19 Vaccine Task Force



Without a dramatically improved data collection and performance management system, we will be unable to:

Maximize CA allocation of vaccine Hit our equity goals • Consistently prioritize our highest risk Total doses delivered to CA¹ 10.5 million populations for vaccinations Total doses administered in CA¹ 8.0 million Know precisely who has been vaccinated on Total doses of inventory in CA¹ 2.5 million the same day Understand equity performance at an \bullet individual provider/site level and make First dose allocations to CA have been flat. We must appropriate changes to improve it demonstrate the ability to administer the vaccine supply we have, in advance of the federal government

 Reserve vaccination appointments statewide for target populations

1 As of 2/25/21



increasing supply rapidly

Source: CA COVID-19 Vaccine Task Force



 \geq

Current state

- Recorded on **multiple systems** (including paper-based at some sites)
- Lags in data reporting
- K Gaps in data reported
- **Difficulty supporting real-time** decisionmaking
- Missing or unaccounted for vaccines
- Inconsistent user experience for access to and getting vaccinated

Future state

- One system for data collection from appointments to vaccine administration
- Enhanced availability of data for data monitoring and tracking as well as reporting
- User-friendly tool for the public to register (via My Turn) for vaccinations
- Consistent tracking for follow-up doses
- ✓ Consistent and integrated user experience





... while supporting the local health jurisdictions and current vaccinators through the power of "and"

How we will support...

Develop a rigorous, reliable, statewide performance management system	and Maintain and enhance the performance of local health jurisdictions		
Get all network providers to adopt the operational and technical changes needed to support the new performance management system	and	Position network providers to succeed without disruption	

Vaccinate equitably, ensuring we are prioritizing the highest risk populations first

and

Vaccinate efficiently, effectively, and rapidly

AND TIME IS OF THE ESSENCE

Source: CA COVID-19 Vaccine Task Force





Transition Plan to a State-Led Direct Allocation to Accelerate Vaccine Distribution and Administration

03/26/2021



Information contained in this file is confidential, preliminary, and pre-decisional



Context

Overview of the TPA direct allocation process

Transition process to direct allocation





Context

The state is changing the way vaccines will be allocated by transitioning to direct-to-provider-site allocation ("push" model). The goals are to maximize distribution efficiency, have real-time transparency into where the vaccines are and to whom they've been administered, and ensure they are distributed to communities disproportionately impacted by COVID-19.





Why is the state transitioning to a direct allocation vaccine process?

DRAFT - AS OF MARCH 21, 2021

Throughout March the State will transition to allocate vaccines directly to providers and their vaccination site(s). Direct allocation supports three primary goals for all Californians:

Equity

• Promote the State's vaccine equity goals by consistently targeting the state's hardest hit communities. The State is setting aside at least 40 percent of vaccine doses for most impacted communities; seeks to reach 2 million vaccine doses in those communities to move counties through tiers and open more activities safely.

A Consistent Experience for Eligibility and Appointments

• A single platform, MyTurn, that allows Californians to learn when they are eligible to be vaccinated and a place to make an appointment when eligible. The State will incorporate MyTurn data into the direct allocation methodology to ensure demand meets supply.

Provider Performance

 The State and TPA will use consistent key performance metrics for all providers to maximize efficiency in the delivery of vaccine (no doses sitting in freezers).

Source: TPA supply chain and communications workstreams





Context

Overview of the TPA direct allocation process

Transition process to direct allocation





DRAFT - AS OF MARCH 21, 2021

Current process

CDPH gives an allocation of vaccine doses to LHJs/MCEs based on CA state-wide allocation

Providers request orders of vaccine for individual sites

LHJ/MCEs review order requests and allocates to sites, based on total allocation and capacity

CDPH compiles LHJ/MCE site level allocation and submits orders to manufacturers

Manufacturers ship vaccine to providers

Direct allocation process for 1st and 2nd doses

- Providers submit site-level capacity, scheduled 2nd dose appointments and inventory each week in myCAvax
- TPA in collaboration with LHJs runs site-level allocation model based on state guidance to allocate vaccine to TPA network
- 3
- TPA recommends and State approves allocation
- - State compiles full allocation and submits orders to manufacturers
- 5
 - Manufacturers ship vaccine to providers

LHJ/MCEs will be asked for recommendations during step 2 (see slide 7)

Source: TPA supply chain and allocation workstreams





DRAFT - AS OF MARCH 21, 2021

Overview of process

The TPA will partner with LHJs/MCEs to identify providers and allocation amount for those providers in their jurisdiction for the next allocation.

The TPA will run an initial site-level allocation, based on the state's criteria and include other data inputs (e.g. inventory levels), to update previous projections.

TPA will seek additional feedback from the LHJs/MCEs after the draft allocation is available.

Once the final CDC allocations are released, the TPA will run a final allocation model.

State makes final decisions.

1 Will be allocated using an HPI weighting Source: TPA supply chain and allocation workstreams



Inputs into the allocation model

- The total doses available for allocation
- Overall weighting based on State criteria (e.g. 16+)
- Equity weighting to reflect the State's equity priorities¹
- LHJ provider recommendations
- Site level metrics, including zip codes served, performance (including success in vaccinating target populations), capacity, storage, inventory-on hand, compliance to network requirements



DRAFT - AS OF MARCH 21, 2021

Individual providers and sites will **no longer request an order through their** LHJ; the State will conduct direct site-level allocation, based on known site-level information.

Each provider site is required to **submit information on a weekly basis through myCAvax**, which will be used to ensure an appropriate allocation for that week and projections for future allocations¹

LHJs will provide feedback on providers' site(s) in their area

Providers report administration metrics to help improve future allocations

1 Sites must be in myCAvax and have capacity data provided in order to receive an allocation

Source: TPA supply chain and communications workstreams





Context

Overview of the TPA direct allocation process

Transition process to direct allocation





- Partner weekly with each LHJ to obtain the LHJs' recommendations for allocation to providers in their communities.
- Develop a detailed transition plan based on dialogue with each local health jurisdiction.
- Maintain account managers for each local health jurisdiction who will function as day-to-day contacts for any issues that arise.
- Collaborate as much as possible with the LHJs given the urgency of our collective situation.
- Ensure there is a reliable, fully staffed process for onboarding to My Turn
- In partnership with the state, develop and communicate a release schedule of additional capabilities in My Turn (e.g., electronic medical record interface, ability to block off appointments and target them to specific populations)
- All while also hitting aggressive deadlines we agreed to with the state.






- For allocations on Tuesday, March 30th, the TPA will begin a push model for all providers that have signed contracts with the TPA. For the time being, providers who have not yet signed a contract with the TPA can still receive allocations via the LHJ.
- By first week of April, only providers who have signed a contract with the TPA or LHJs who signed an MOU with the state will be able to receive allocations. Any 2nd dose requirements will be fulfilled.
- For the March 23rd allocation ordered by Thursday, the normal process of allocation by the LHJ to providers will occur. The only exception are those counties who have already transitioned as Wave 1 counties.
- In addition to this normal work, LHJs are asked to fill out a spreadsheet by Wednesday, March 24 of this week
 indicating how much vaccine should be allocated to each provider in their jurisdiction for the March 30th
 allocation. The information provided by the LHJ will be a key driver of the allocations.
- The push model for the week of March 30th will be a combination of direct allocation by the State / TPA for
 providers who have signed onto the TPA network, and the remainder of allocations going through the normal
 LHJ allocation process. Note: This dual workload will continue for a couple of weeks until the system is
 completely transitioned to the statewide TPA network.



Provider Office Hours Q&A

Please use the Q&A panel to comment or ask a question:

Q&A Panel







Together we can end the pandemic.

CA Department of Public Health Trust & Safety Team

Local Health Jurisdictions and Providers

Friday, March 26, 2021 For Discussion Purposes Only



CDPH Trust and Safety Team Overview

Mission

The California Department of Public Health (CDPH) Trust and Safety Team identifies, analyzes, and provides options for responding to misinformation and disinformation (mis/dis) and other narratives in online and social media that pose risks to public COVID-19 vaccine acceptance in California.

Key Activities

The CDPH Trust and Safety Team consists of Sensing & Analysis and Partnerships teams that perform two key sets of functions:




Use social listening tools and analytical methodologies to identify, analyze, and report on mis/dis and other narratives that pose risks to public COVID-19 vaccine acceptance in California.

Provide response options to address mis/dis and other narratives; establish and strengthen partnerships with communitybased organizations, federal, state, local, territorial, and tribal governments, social media platforms, academia, and law enforcement.



Defining Misinformation and Disinformation (Mis/Dis)

- **Misinformation** is <u>unknowingly</u> false or misleading information crafted and disseminated <u>without</u> the intent to harm, deceive, or manipulate an audience.
- **Disinformation** is <u>deliberately</u> false or misleading information crafted and disseminated <u>with</u> the intent to harm, deceive, or manipulate an audience.





Examples of Content to Report



The following posts are examples of content that should be shared with the Trust and Safety Team through the Rumors Inbox for awareness and possible action.

Rizza Islam @IslamRizza · Feb 28 Precisely	•••
🝘 Matt Man @madmu5icjunky · Feb 26	
Well, I officially know more people that have died within a week of taking the vaccine than I do of people that died from COVID	



Unfounded doubts about the safety and efficacy of COVID-19 mRNA vaccines, particularly if promoted by prominent celebrities or community influencers.

"CDC/FDA Adverse Incident Reports Show 966 Deaths Following Vaccination for COVID-19" -- by Celia Farber, @EpochTimes (Gab, Substack: @CeliaFarber)



Adverse Incident Reports Show 966 Deaths Following Vaccination for COVID-19 According to adverse incident reports collected by the Centers for Disease Control and Prevention (CDC) and the Food ... & theepochtimes.com

Use of manufactured medical data or misuse of actual medical data that could increase doubt in the COVID-19 vaccines' safety.



If found, report it to rumors@cdph.ca.gov

Working Together

Your Role

- Help identify COVID-19 vaccine rumors Share potential false claims, confusing information, and potential mis/dis that you hear or see in your communities with <u>Rumors@cdph.ca.gov</u>.
- Share out the facts Share COVID-19 vaccine facts, information, and content across your channels from authoritative sources to inform and educate the public.

Our Role

- **Provide regular reporting** We will provide a regular bi-weekly report on narratives that pose risks to public COVID-19 vaccine acceptance in California.
- Identify authoritative content We will pass along timely and accurate information about COVID-19 vaccines and the vaccination campaign to share back with your communities.

If found, report it to rumors@cdph.ca.gov

Thank you

Questions?



Trust and Safety Partnerships Team

Hayley Cain: <u>Hayley.cain@cdph.ca.gov</u> Angela Eaddy: <u>Angela.eaddy@cdph.ca.gov</u> Lindsay Sapienza: <u>Lindsay.Sapienza@cdph.ca.gov</u>




If found, report it to rumors@cdph.cd.gov

Provider Office Hours Q&A

Please use the Q&A panel to comment or ask a question:

Q&A Panel





Core Areas of Sensing: Themes

The Trust and Safety Team has identified the following themes with related narratives that may pose risks to public COVID-19 vaccine acceptance in California. These themes will likely evolve over time.

COVID-19 vaccine distribution and administration is flawed

- Ex. Narrative: California is prioritizing vaccinating the rich and powerful.
- Ex. Narrative: Undocumented individuals will have to pay for a COVID-19 vaccine out of pocket.



Concern about COVID-19 is not justified

- Ex. Narrative: COVID-19 is a hoax by "elites and insiders" for personal gain and profit.
- Ex. Narrative: COVID-19 vaccines are unnecessary because treatments already exist for those who contract COVID-19.



COVID-19 vaccines cause adverse effects

- Ex. Narrative: The safety and efficacy of the COVID-19 vaccines can't be trusted because the development timelines were rushed and used new and unproven technologies.
- Ex. Narrative: The COVID-19 vaccines have caused allergic reactions in the elderly and killed hundreds of people.



Announcements



Weekly VA58 Newsletter – Amy Pine

- Top California doctors tout Johnson & Johnson COVID vaccine
- ✓ New <u>expanded</u> vaccination eligibility
- ✓ All nine Bay Area counties issue joint statement on Johnson & Johnson COVID-19 vaccine
- ✓ There's no such thing as a second-class COVID vaccine

To subscribe, email <u>VA58@cdph.ca.gov</u> and put "please add me to the weekly VA58 newsletter list" in subject line.

VA58 Weekly Newsletter: Sharing Information From Our Team to Yours

The Vaccinate ALL 58 Weekly Newsletter is meant to share the latest news, key messages, tools and resources around the vaccine and to help keep you up to date on what's happening at the federal, state and local level.

Ideas? Newsletter-related questions? Send us a note at VA58@cdph.ca.gov.

Weekly Updates March 18, 2021 **Total Doses**

Administered in Vaccinate ALL 58 Together we can end the pandemic.

California: 13,382,046 "Numbers do not represent true day-today ohange as reporting may be delayed.

Monitoring Mis- and Disinformation

CDPH has established a Trust and Safety team committed to making sure the public has accurate and timely information on COVID-19 vaccination across the State. If you see or hear of any vaccine-related rumors across social media or in your communities, share them with the Trust and Safety team at Rumors@cdph.ca.gov for awareness and possible action. Scroll down in this week's newsletter to see how to combat myths with facts.

Send an Email

This Week?

From the State

For Providers Letter from CDPH Director to All

Vaccination Providers

 Two Million COVID-19 Vaccine **Doses Delivered to California's** Hardest-Hit Communifies

· CDPH Launches "Let's Get to ImmUnity" Campaign to Boost COVID-19 Vaccine Acceptance See Fact Sheet Regarding Vaccines for People with High-**Risk Medical Conditions or Disabilities**

 The My Turn COVID-19 Scheduling System Expanding to Include Six Additional Languages, for a Total of 14

One in four CA adults have received at least one vaccine dose

What's Making News Top California doctors tout Johnson & Johnson COVID vaccine

New expanded vaccination eligibility







- Amy Pine Jansen COVID-19 Vaccine Educational Webinars

- Information for healthcare
 providers administering vaccine
- Multiple time/date options
- To register, please visit JanssenCOVID19VaccineWebinar.com

Janssen Thfectious Diseases & Vaccines Pruntaceurical contraines or formore-formers			Educational Webinar		
Meetings	Resources		Your Time Zone: Pacific		
mergency Use Authors he emergency use of nedical product unde	orization (EUA) fi of this product is a r Section 564(b)(tot been approved or licensed by the U.S. Food and Drug Administra or active immunization to prevent Coronavirus Disease 2019 (COVID suthorized only for the duration of the declaration that circumstances 1) of the FD&C Act, unless the declaration is terminated or authoriza coine Important Safety Information below.	D-19) in individuals 18 years of age and older. s exist justifying the authorization of the emergency use of th		
MEETIN	G SEL	ECTION CENTER	Click Schedule Now to begin the registration p		
Week	~	Topic 🗸	Vie		
Tue, Mar 23, 2021	1:00 PM ET	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Wed, Mar 24, 2021	3:00 PM ET	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Thu, Mar 25, 2021	7:00 PM ET	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Fri, Mar 26, 2021	1:00 PM ET	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Mon, Mar 29, 2021	1:00 PM ET	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD		
Tue, Mar 30, 2021	7:00 PM ET	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Wed, Mar 31, 2021	12:00 PM PT	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Thu, Apr 1, 2021	4:00 PM PT	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		
Fri, Apr 2, 2021	12:00 PM PT	Janssen COVID-19 Vaccine: Information for Healthcare Provide Administering Vaccine	Rick Nettles, MD Schedule Now		

Do not administer the Janssen COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Jansser COVID-19 Vaccine.

WARNINGS AND PRECAUTION

Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an
acute anaphylactic reaction occurs following administration of the Janssen COVID-19 Vaccine.

Monitor Janssen COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdo.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

- Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Janssen COVID-19 Vaccine.
- Limitations of Vaccine Effectiveness: The Janssen COVID-19 Vaccine may not protect all vaccinated individuals.

ADVERSE REACTIONS

Adverse reactions reported in a clinical trial following administration of the Janssen COVID-10 Vaccine include injection site pain, headache, fatigue, myalgia, nausea, fever, injection site erythema and injection site swelling. In clinical studies, severe allergic reactions, including anaphylaxis, have been reported following the administration of the Janssen COVID-10 Vaccine.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Janssen COVID-19 Vaccine

My Turn available in Multiple Languages – Amy Pine

Full Functionality in 12 Languages!

- ✓ Armenian
- ✓ Simplified Chinese
- ✓ Traditional Chinese
- ✓ Japanese
- ✓ Khmer
- ✓ Korean
- ✓ Punjabi
- ✓ Russian
- ✓ Spanish
- ✓ Tagalog
- ✓ Vietnamese
- ✓ English





Вакцинация против коронавирусной инфекции COVID-19: узнать, когда наступит ваша очередь

У каждого человека в Калифорнии будет возможность пройти вакцинацию против коронавирусной инфекции COVID-19 бесплатно. Однако в данный момент наши поставки вакцин ограничены. Поэтому мы начинаем вакцинацию с групп повышенного риска, таких как люди с высокой вероятностью заразиться, а также люди от 65 лет и старше.

Соответствуете ли вы критериям?

Чтобы узнать, когда наступит ваша очередь, ответьте на несколько вопросов. Это займет всего несколько минут. Если вы соответствуете критериям, а запись на вакцинацию доступна через My Turn, вы можете запланировать запись на прием. Если ваша очередь еще не наступила, либо нет доступного времени для записи на прием, вы можете зарегистрироваться, чтобы получить уведомление о том, когда вы будете соответствовать критериям либо когда откроется дополнительное время для

2anucu Español English 简化字 Tagalog 한국어 正體字 Tiếng Việt 평활() 평생 **pycckuň** 英語 Uluqitptů ਪੰਜਾਬੀ

русский

VaccinateALL58:Communications Report – Asbury Jones


CDPH "Let's Get to Immunity" Campaign

Multicultural & African American Social Media Ads











VaccinateALL58:Communications Report – Asbury Jones

Multicultural TV Ad



https://youtu.be/eyhaxTinO8c



Vaccine Updates



Administration and Allocation

Amy Pine



Eligibility Expansion is Coming Soon!



FOR IMMEDIATE RELEASE: Thursday, March 25, 2021 Contact: Governor's Press Office (916) 445-4571

State Expands Vaccine Eligibility to 50+ Californians Starting April 1 and All Individuals 16+ on April 15 Based on Expected Supply Increases

Even with increased vaccine supply, vaccination of willing Californians will take several months

State supporting trusted providers and counties for non-traditional outreach in hard-toreach communities

SACRAMENTO - With supply of vaccines expected to significantly increase in the coming weeks, the state is expanding vaccine eligibility to more Californians. Starting April 1, individuals aged 50+ will be eligible to make an appointment, and individuals 16+ will be eligible to make an appointment to be vaccinated starting on April 15.

"With vaccine supply increasing and by expanding eligibility to more Californians, the light at the end of the tunnel continues to get brighter," said Governor Newsom. "We remain focused on equity as we extend vaccine eligibility to those older than 50 starting April 1, and those older than 16 starting April 15. This is possible thanks to the leadership of the Biden-Harris Administration and the countless public health officials across the state who have stepped up to get shots into arms."

The state has the capacity to administer more than 3 million vaccines per week, and is building the capacity to administer 4 million vaccines weekly by the end of April.

When you can get vaccinated

California is allocating COVID-19 vaccines as they become available to ensure equitable distribution. Vaccinations are prioritized according to risk and age.

Healthcare workers and long-term care residents (Phase 1A)

Now vaccinating

People with a high chance of exposure and those 65 or older (Phase 1B)

Now vaccinating

Sector populations with high chance of exposure:

- Agriculture and food
- · Education and childcare
- Emergency services

Individuals age 16 or older at higher risk

Now vaccinating

People with certain significant high-risk:

- Medical conditions
- Disabilities
- Illnesses
- Living spaces
- Work environments

Individuals 50 or older

Starts April 1, 2021

Every Californian 16 or older

Starts April 15, 2021


Vaccination of people younger than 16 will start as soon as the COVID-19 vaccines are approved for them

See CDPH's Updated COVID-19 Vaccine Eligibility Guidelines 12 for details



Doses Administered (3/24)

Vaccines - Coronavirus COVID-19 Response (ca.gov)




Note: Doses delivered includes the CDC Long Term Care (LTC) Pharmacy Partnership Program and Federal Retail Pharmacy Partnership Program. This does not include doses delivered to the following federal agencies: Indian Health Service, Veterans Health Administration, Department of Defense, and Federal Bureau of Prisons. The CDC LTC Pharmacy and Federal Retail Pharmacy Partnership Program doses are a evideat of the drose delivered.

Data: 3/24/2021 11:59pm | Posted: 3/25/2021

 $\leftarrow \rightarrow \vdash \ll \square$

∰ +ab |eau



Least healthy community conditions

Most healthy community conditions

Updated March 25, 2021 with data from March 24, 2021. Excludes doses without an HPI score, including out-of-state residents or records with missing zip codes. Percentage for doses calculated as doses administered in a quartile divided by total doses administered statewide.



CA's Allocation (3/23)

	Doses	Boxes
Janssen	44,000	440
Pfizer	644,670	551
Moderna	380,300	3803
Total	1,068,970	4,794



1518COV30

6.COV2.S21

200162

4381242

anssen Vaccines

AC31518COV

126.COV2.51

200162

02

VAC. Ad26.

1)2001

04

2) 4381242

Janssen Va

VAC31518

Ad26.COV

1)2001

00

VAC31518C0W

Janssen Vaccine

VAC31518C0V Ad26.COV2.S

1)200162

08 2) 4381242

Ad26.COV2.8

1)200162

03

2) 4381242

- ✓ Supply remains limited for eligible population
- ✓ Supply expected to INCREASE mid-April
- Prioritize second doses over immunizing additional patients with first doses

Posted on <u>Vaccinate all 58</u> website:

- Doses on-hand by provider
- Weekly allocations of vaccine by health jurisdiction and multicounty-entity (MCE)

myCAvax

Claudia Aguiluz



TPA Transition & myCAvax functionality

rror Messa	ge: Order o	cannot be p	laced for in	-TPA-networ	[·] k	Once in the TPA network, orders functionality will l disabled. Instead, sites will be submitting a Weekly Vaccination Capacity Form
ຝ ☉ https://uatca	-calvax.cs33.force.com/s/or	rder		ର୍ ହ	0 1= 1	New Vaccination Capacity
	r organisation to compress myCkillar enforme	is placed for in TF S n. Bo <u>l</u> ocion inseyo/ognisionper		200	0	
3 tems + upcaried a few seconds ago			Q, Sear	art 5. 1.	C / C T	How many total second dose appointments do you have scheduled for the next two weeks, by vaccine type?
Order Number	✓ Account Name	✓ Order Amount	✓ Order Start Date	✓ Satur	~	Search Products
1 00002962	Queent	80.00	2/5/2021	Complete	•	Week 1 Dose 2 Appointments Scheduled - 1 O Week 2 Dose 2 Appointments Scheduled - 1 O
2 00028981	Queent	80.00	\$52221	Suomieso	۲	Vacone 2 Search ProductsQ
\$ 00024394	Queenn	80.00	992221	Perding	•	Week 1 Dose 2 Appointments Scheduled - 2 • vveek 2 Dose 2 Appointments Scheduled - 2 •
						Cance Save 5 N



TPA Transition & myCAvax functionality

between bookers. Calenda Calenda <th>New Vao</th> <th>cination Capacity</th> <th></th> <th></th> <th></th> <th></th> <th>Transfer/Redistribution Wast</th> <th>le Excursion Shij</th> <th>pment Incide</th>	New Vao	cination Capacity					Transfer/Redistribution Wast	le Excursion Shij	pment Incide
New Start Nonag/ **vee: 5 Max Apportment Capacity **vee: 1 Max Apportment Capacity **vee: 1 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Capacity **vee: 2 Max Apportment Scineouse of the next two weeks, by vaccine type? **vee: 2 Cose 2 Apportments Scineouse of 1 **vee: 2 Cose 2 Apportments Scineouse of 1 </th <th>formation Proviser Location Bearch Accounts</th> <th>۹.</th> <th>0 items • Sorted by Asset Name • Filtered b</th> <th>y Ali vaccine Inventory • Updated a</th> <th></th> <th></th> <th></th> <th></th> <th></th>	formation Proviser Location Bearch Accounts	۹.	0 items • Sorted by Asset Name • Filtered b	y Ali vaccine Inventory • Updated a					
Second Products Second Products Versil 2 Dose 2 Appointments Scheduled - 1 Image: Shipment b Image: Shipment b	lowing Monday. Neek Start (Monday) I all Neek 1 Max Apportment Capabity	*Week 2 Max Appointment Capacity		e Organization	Locations Vaccine Orders Va	ocine Inventory Commun	ication More 🗸		 م
Search Products Quest Clinics Price Differ Differ <thdiffer< th=""> Differ <thdiffer< th=""></thdiffer<></thdiffer<>	Isone 1 Search Products Q Reix 1 Dose 2 Appointments Scheduled - 1 🕐			y All shipment • Updated a few sec	conds ago		Q. Search this list	\$ ×	Ē • C
2 SHIP-008197 Queen1 Moderna COVID-19 Vaccine 00002952 2,530 8/16/2021		veex 2 Dose 2 Appointments Schequed - 2 0							
			4 SHIP-008140	Queen1	Moderna COVID-19 Vaccine	00002952	2,000		



Reporting Shipping Incidents

Reporting Shipment Incidents

California COVID-19 Vaccination Program



Vaccine shipments must be received and inspected immediately upon arrival. (See Receiving & Storing Pfizer | Moderna | Janssen Vaccine for details.) Report all shipment incidents for vaccine product or kits (including product viability, damage or packing slip discrepancies) the same day the shipment arrived at the office as documented by the carrier.

Centrally Distributed Vaccines (McKesson)

Moderna and Janssen vaccines and standard ancillary supply administration kit ship from McKesson. McKesson requires that shipment incidents be reported the day of receipt for resolution.

- Shipping packing slip must be compared against what was ordered and contents in the box; any
 discrepancies (e.g., missing doses or overage) must be reported immediately upon discovery
- Note the box (if multiple boxes were received) and its tracking number
- Scan and attach the packing list for all incidents
- Include picture of the TagAlert temperature monitoring device and its location in the shipping container (for temperature excursions only)

Login to the myCAvax provider system and click **Vaccine Inventory** to gather the information needed to resolve the shipping incident. Then contact the manufacturer or McKesson to resolve the incident directly and report the case number and any resolution in your shipment incident report.

	Point of Contact	Contact Info
General Vaccine Shipment Issues	McKesson Customer Service	Phone: 833-343-2703
Temperature Excursions during shipment	McKesson Customer Service	Vaccine Viability – Temperature Excursions during shipment for McKesson Specialty Distributed COVID Vaccine. Questions/concerns about vaccine viability issues during shipment must be reported on the <u>same day as</u> <u>delivery</u> . Phone: (833) 272-6635 Monday – Friday, 8 a.m 8 p.m. ET Email: COVIDVaccineSupport@McKesson.com (only send email if after hours)
Ancillary kit issues	McKesson Customer Service	Phone #: 833-272-6634 Email: SNSSupport@McKesson.com

California COVID-19 Vaccination Program


IMM-1342 (3/16/21)

Vaccine shipments must be received and inspected immediately upon arrival.

- Report all shipment incidents for vaccine product or kits (including product viability, damage or packing slip discrepancies) <u>the</u> <u>same day</u> the shipment arrives at the office as documented by the carrier.
- ✓ Login to the myCAvax and click Vaccine Inventory to gather the information needed to resolve the shipping incident. Then, contact the manufacturer or McKesson to resolve the incident directly, and report the case number and any resolution in your shipment incident report.



Reporting Shipping Incidents



- Login to myCAvax and click Vaccine Inventory to gather the information needed to resolve the shipping incident.
- Then, contact the manufacturer or McKesson to report the incident directly and report the case number and any resolution in your shipment incident report.
- Important: If product is missing, you will need to document the # of missing products and the affected boxes (if multiple boxes were received).

ago	
Number V Account Name V Total Dose	s V Doses Available V Expiration Date V
Shipment Incident	
S-0110	F
DETAILS RELATED	
 Step 1 :Shipment Incident 	
Account	Status
Queen1	Open
Date shipment was received 3/25/2021	Resolution
Product	Shipper
Moderna COVID-19 Vaccine	McKesson
	Lot Number
	856
✓ Step 2: Incident Details	
Incident type	Incident related to
Out-of-range temperature	Vaccine
Tracking Number 2365	Packing Silp for Correct Provider
Number of doses impacted (damaged)	Packing Silp matches Shipping Label
400	✓
Number of missing doses/viais	
Number of additional doses/vial trays	
Hernoel of abultorial duses via days	
Number of missing diluents	
Additional Comments	
 Step 3: Manufacturer/Shipper communication 	tion
Case or Incident number	Guldance/resolution

Storage & Handling

Kate McHugh



Pfizer-BioNTech 6th Dose and Low Dead-Volume Syringes


- New FAQs released by United States Pharmacopeia (USP) address common questions related to low dead-volume (LDV) syringe and needle combinations in the Pfizer-BioNTech ancillary kit and extraction of a sixth dose per vaccine vial.
- Practice settings have reported success using a combination o 3 LDV syringes and 3 non-LDV syringes for vaccine withdrawal. To ensure success, the CDC is shipping ancillary kits with approximately 80% LDV syringes and 20% non-LDV syringes.
- This 5:1 ratio should ensure providers are able to obtain all six doses from the Pfizer-BioNTech vial. For additional information see: <u>FAQ for Optimizing COVID-19 Vaccine Preparation and</u> <u>Safety (ashp.org)</u>.





Vaccine Waste

- It is required to track, document, and report! This is a requirement outlined in your provider agreement.
 - \circ Report to myCAVax
 - $_{\odot}$ Even one dose wasted should be reported!
 - $_{\odot}$ Report when you can't pull 6 doses out of Pfizer
- Common reasons for waste:
 - Dilution errors (Pfizer) or syringes were drawn up with the incorrect dosage
 - Pre-drew too many doses and beyond use time was reached
 - $_{\odot}$ Dropped syringes or syringe malfunctioned or leaked





Preventing Vaccine Waste

- CDPH will release resources in the near future
- Pay careful attention to how many doses are being pre-drawn or removed from the refrigerator at mass vaccination clinics
- Have a list of potential patients on standby to call in at the end of the day for unused doses
- Inspect the syringe/needle prior to drawing up the vaccine, tighten if needed
- Staff training on dilution and drawing up doses
- Keep a close eye on Beyond Use and expiration dates

 Contact your LHD if you have vials that will be expiring soon and need help with a plan





CDPH is Monitoring Vaccine Waste

- We are tracking waste by provider
- We will contact high-waste producing providers to help them work on improvement measures if waste events increase beyond levels that are deemed appropriate
- Vaccine inventory is very limited, so we all need to work to ensure we are wasting as little as possible to best serve the public
- Many providers are very diligent about reporting waste, please keep up the good work!



Provider Call Center

Brenton Louie



Correction from last week

Who can submit orders in myCAvax?

Location Coordinators and Organization Coordinators can both submit vaccine order requests in myCAvax on behalf of a location.



Update Account Info in myCAvax

- Ensure refrigerator and freezer information is up to date!
 - Organization and Location Coordinators can log in to myCAvax to update account information
 - Contact myCAvax Help Desk if you're unable to edit a field myCAvax.HD@Accenture.com
- Shipment Incidents report immediately!
 - $_{\odot}$ Count vaccines to verify they match the packing slip.
 - $_{\odot}$ Count ancillary supplies to verify they match the packing slip.
- Log in to your myCAvax account routinely to avoid deactivation.



COVID-19 Provider Call Center: Contact Us!

For questions from Providers/LHJs regarding the COVID-19 Vaccine Program:

Email: <u>covidcallcenter@cdph.ca.gov</u> Phone: (833) 502-1245, M-F 8 AM – 8 PM






Provider Office Hours Q&A

Please use the Q&A panel to comment or ask a question:

Q&A Panel





Your Feedback is Important to Us

Poll: How helpful was today's Provider Office Hours to your work?

- A. Very helpful
- B. Helpful
- C. Somewhat helpful
- D. Slightly helpful
- E. Not helpful at all





Thank you



for our next weekly Provider Office Hours Friday, April 2nd 9:00 AM



Provider Resources

COVID-19 Provider Call Center – for questions related to the COVID-19 Vaccine Program

- Email: <u>covidcallcenter@cdph.ca.gov</u>
- Phone: (833) 502-1245
 Monday Friday from 8 AM–8 PM

myCAvax Technical Help – for technical questions

Email: <u>myCAvax.HD@accenture.com</u>

My Turn – for questions regarding My Turn application

- Email about onboarding: <u>myturnonboarding@cdph.ca.gov</u>
- Email about general questions: <u>myturninfo@cdph.ca.gov</u>

Third-Party Administrator Blue Shield of California

• <u>TPA_Inquiry@Blueshieldca.com</u>

(Note: There is an underscore "_" between TPA and Inquiry.)

	California COVID-19 Vaccination Program Provider FAQs v. 9; 3.3.
	California COVID-19 Vaccination Program Provider FAQs
Pro	For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. oviders may also visit <u>California COVID-19 Vaccination Program</u> for information and updat
Dir	ections: Click on a category to be directed to related FAQs.
Со	ntents
1.	TPA, My Turn
2.	Provider Eligibility and Enrollment
3.	Allocation
4.	Ordering
5.	Distribution/Redistribution
6.	Vaccine Storage & Handling
7.	Phases & Tiers
8.	Vaccine Administration
9.	Inventory
10	Reporting
11	. Costs & Reimbursement
12	. Communication Resources

https://eziz.org/assets/docs/CO

ID19/Vax58ProviderFAQs.pdf

